Comparative Pharmacology
Head-to-head clinical analysis: GONAL F RFF REDI JECT versus HUMEGON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GONAL F RFF REDI JECT versus HUMEGON.
GONAL-F RFF REDI-JECT vs HUMEGON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian follicles, stimulating follicular growth, maturation, and estrogen production.
HUMEGON (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from the urine of postmenopausal women. It acts by stimulating ovarian follicular growth and maturation in women and spermatogenesis in men via binding to FSH and LH receptors on target cells.
Subcutaneous injection. Initial dose 75-225 IU once daily for 7-14 days, titrated based on ovarian response. Maximum daily dose 450 IU.
75 to 150 IU subcutaneously or intramuscularly once daily for 7 to 12 days, adjusted based on follicular response.
None Documented
None Documented
Terminal elimination half-life: approximately 24 hours; clinically, steady-state is achieved within 3-5 days of daily dosing.
Terminal half-life approximately 23-24 hours (range 20-30 h) for FSH and LH activity; clinical significance: once-daily dosing achieves steady-state in 4-5 half-lives (approx. 5 days).
Renal: approximately 70-80% of the dose; fecal: <20%
Primarily renal (90-95% as intact hormone and metabolites); biliary/fecal excretion minor (<5%).
Category C
Category C
Gonadotropin
Gonadotropin